WWL70

CAS No. 947669-91-2

WWL70( —— )

Catalog No. M22473 CAS No. 947669-91-2

WWL70 is a selective alpha/beta hydrolase domain 6 inhibitors (IC50: 70 nM). WWL70 (10 μM, 1 h) treatment, 2-Arachidonoylglycerol is increased by 20% compared to untreated cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 82 In Stock
10MG 126 In Stock
25MG 248 In Stock
50MG 423 In Stock
100MG 599 In Stock
200MG 834 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WWL70
  • Note
    Research use only, not for human use.
  • Brief Description
    WWL70 is a selective alpha/beta hydrolase domain 6 inhibitors (IC50: 70 nM). WWL70 (10 μM, 1 h) treatment, 2-Arachidonoylglycerol is increased by 20% compared to untreated cells.
  • Description
    WWL70 is a selective alpha/beta hydrolase domain 6 inhibitors (IC50: 70 nM). WWL70 (10 μM, 1 h) treatment, 2-Arachidonoylglycerol is increased by 20% compared to untreated cells. WWL70 (either 1 or 10 μM) completely blocks the lipopolysaccharide (LPS)-induced increase of PGE2. The enhanced mRNA expression of mPGES-1 and mPGES-2 by LPS is also reduced by WWL70. The IC50 of WWL70 to inhibit the PGE2 biosynthesis is about 100 nM.WWL70 treatment completely restores the ability of TBI mice to continuously alternate arms during Y maze exploration (69.67±4.98 %). WWL70 treatment improves motor coordination of traumatic brain injury mice in a concentration-dependent manner. The latency to fall in animals treated with WWL70 (5?mg/kg) increases from 74.92±4.8 to 99.57±5.21 on day 3 (p<0.01) and from 87.32±4.42 to 100.14±3.56 on day 7 (p<0.05) post-injury when compare with the vehicle-TBI groups. WWL70 (10?mg/kg) treatment improves motor coordination starting on day 1 post-injury.
  • In Vitro
    At 1 h after WWL70 (10 μM) treatment, 2-Arachidonoylglycerol (2-AG) is increased by 20% compare to untreated cells. At either 1 or 10 μM, WWL70 completely blocks the lipopolysaccharide (LPS)-induced increase of PGE2. The enhanced mRNA expression of mPGES-1 and mPGES-2 by LPS is also reduced by WWL70. The IC50 of WWL70 to inhibit the PGE2 biosynthesis is about 100 nM.
  • In Vivo
    Although post-treatment with WWL70 at 5?mg/kg does not have any effect, treatment with WWL70 at 10?mg/kg improves the performance significantly. WWL70 treatment improves motor coordination of traumatic brain injury (TBI) mice in a concentration dependent manner. The latency to fall in animals treated with WWL70 at 5?mg/kg increases from 74.92±4.8 to 99.57±5.21 on day 3 (p<0.01) and from 87.32±4.42 to 100.14±3.56 on day 7 (p<0.05) post-injury when compare with the vehicle-TBI groups. At 10?mg/kg, WWL70 treatment improves motor coordination starting on day 1 post-injury. WWL70 treatment completely restores the ability of TBI mice to continuously alternate arms during Y maze exploration (69.67±4.98 %).
  • Synonyms
    ——
  • Pathway
    Wnt/Notch/Hedgehog
  • Target
    Wnt/beta/catenin
  • Recptor
    ABHD6
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    947669-91-2
  • Formula Weight
    437.49
  • Molecular Formula
    C27H23N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:17.33 mg/mL (39.61 mM; Need ultrasonic)
  • SMILES
    CN(Cc1cccc(c1)-c1ccncc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Li W, et al. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J Am Chem Soc. 2007 Aug 8;129(31):9594-5.
molnova catalog
related products
  • Ipafricept

    Ipafricept (OMP-54F28) is a recombinant fusion protein consisting of the extracellular portion of the human frizzled-8 receptor fused to a fragment of human IgG1 Fc, and a Wnt inhibitor that blocks Wnt signaling.

  • Pamidronic acid

    Pamidronic acid Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells.

  • Zinc Orotate

    Orotic acid zinc salt dihydrate is an intermediate product in pyrimidine synthesis.